Scientists probe immune cells to unlock vasculitis mysteries
NCT ID NCT01862068
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how certain immune cells, called neutrophils, behave in people with granulomatosis with polyangiitis (GPA), a rare blood vessel inflammation disease. Researchers collected blood samples from 93 participants, including patients with GPA and other related conditions, as well as healthy volunteers. The goal was to find proteins that could help doctors better track disease activity and guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could lead to better ways to monitor disease activity and more targeted, better-tolerated treatments for vasculitis.
- What could go wrong
- This is an observational study, not a treatment trial. It aims to understand the disease, not test a new therapy, so direct patient benefits are not immediate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
93 people
The number who actually took part.
- Started
-
May 2012
- Finished
-
May 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
GPA (Granulomatosis with polyangiitis) patients and MPA ( Microscopic Polyangiitis) with an active disease at inclusion
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For patients with GPA * Systemic or localized GPA with ACR (American College of Rheumatology) criteria. * BVAS \> 3. * ANCA anti-PR3 or anti-MPO * Consent form signed For patients with MPA * Systemic MPA with Chapel Hill criteria. * BVAS \> 3. * ANCA anti-MPO * Consent form signed For patients with EGPA * Systemic EGPA with ACR (American College of Rheumatology) criteria. * BVAS \> 3. * ANCA anti-PR3 or anti-MPO * Consent form signed For atherosclerotic patients * Ischemic stroke * Coronary heart attack * Peripheral vascular disease responsible for intermittent claudication * Carotid Stenosis Exclusion Criteria: * Pregnancy * \<18 yr * Malignancy * Infectious diseases: HIV, HBV, HCV
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Eosinophilic granulomatosis with polyangiitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cochin Hospital
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- New hope for Wegener's patients: drug aims to stop flare-ups
- New hope for rare vasculitis: Three-Drug trial targets Non-Responders
- Steroid showdown: can a tiny daily dose keep a rare disease at bay?
- New hope for rare disease: can NS-229 help patients reduce steroids?